RxDoctor Payments Data

Suying Wu, MD

Neurology · Elkhart, INNPI 1669477816

Payments from drug & device makers

$12,054in general payments, 2019–2025

Across 648 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$933
  • Bristol Myers Squibb$866
  • Catalyst Pharmaceuticals, Inc.$809
  • Jazz Pharmaceuticals Inc.$791
  • UCB, Inc.$671
  • Novartis$585
  • plus $7K from 53 others

What the payments were for

  • Speaking & faculty fees$931%
  • Food & beverage$11,94899%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)51$933
Bristol Myers Squibb41$866
Catalyst Pharmaceuticals, Inc.32$809
Jazz Pharmaceuticals Inc.33$791
UCB, Inc.44$671
Novartis43$585
Argenx US, Inc.21$497
Biogen18$454
EMD Serono, Inc.26$409
Amgen(2 entities)18$355
Teva Pharmaceuticals USA, Inc.21$334
Sanofi16$326
Eisai Inc.15$325
Genentech USA, Inc.14$291
Banner Life Sciences, LLC14$284
SK Life Science, Inc.13$269
Neurocrine Biosciences, Inc.14$261
Axsome Therapeutics, Inc.12$245
Lundbeck LLC12$239
AstraZeneca12$229
Acadia Pharmaceuticals Inc14$227
Pfizer15$225
Livanova USA, Inc.22$215
Lilly USA, LLC11$171
Sunovion Pharmaceuticals Inc.16$159
Vanda Pharmaceuticals Inc.4$139
Adamas Pharmaceuticals, Inc.8$131
Piramal Critical Care8$130
Mallinckrodt Hospital Products Inc.6$117
TG Therapeutics, Inc.4$100
Acorda Therapeutics, Inc5$93
Supernus Pharmaceuticals, Inc.5$91
Ipsen Biopharmaceuticals, Inc5$90
Biohaven Pharmaceutical Holding Company Ltd.4$81
Alnylam Pharmaceuticals Inc.4$76
Sumitomo Pharma America, Inc.4$75
Amneal Pharmaceuticals LLC3$65
Merck4$58
Tanabe Pharma America, Inc.3$55
Johnson & Johnson4$52
Avanir Pharmaceuticals, Inc.3$49
Idorsia Pharmaceuticals US Inc3$49
Biohaven Pharmaceuticals, Inc.3$48
Nevro Corp.1$44
Amylyx Pharmaceuticals, Inc.2$38
Grifols USA, LLC2$38
Boston Scientific1$36
Saol Therapeutics Inc.2$33
MDD US Operations, LLC2$29
Cycle Pharmaceuticals Inc1$24
Kyowa Kirin, Inc.1$20
Novo Nordisk1$18
Avadel CNS Pharmaceuticals, LLC1$18
Octapharma USA, Inc.1$16
Abbott1$15
Chiesi USA, Inc.1$15
Otsuka America Pharmaceutical, Inc.1$15
Merz Pharmaceuticals, LLC1$14
Zyla Life Sciences, Inc.1$14

How this compares

$12,054 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$198,862
Medicare patients
572
Services billed
8,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride11$113,083
FycompaPerampanel45$70,467
NuplazidPimavanserin Tartrate12$59,972
AptiomEslicarbazepine Acetate37$54,166
Teriflunomide13$43,833
VimpatLacosamide16$27,697
Glatiramer Acetate12$16,986
Emgality PenGalcanezumab-Gnlm17$11,664
Nurtec OdtRimegepant Sulfate11$11,436
Aimovig AutoinjectorErenumab-Aooe13$11,229
Memantine Hcl ErMemantine Hcl68$9,069
Levetiracetam265$8,518
Ajovy SyringeFremanezumab-Vfrm11$7,934
BelsomraSuvorexant16$6,785
Memantine Hcl148$6,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$325$70,46745 claims
Acadia Pharmaceuticals IncNuplazid$227$59,97212 claims
Sunovion Pharmaceuticals Inc.Aptiom$159$54,16637 claims
UCB, Inc.Vimpat$671$27,69716 claims
PfizerNurtec Odt$225$11,43611 claims
MerckBelsomra$58$6,78516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →